David Shaw’s Cellebrite CLBT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.27M Buy
+290,230
New +$3.86M ﹤0.01% 2817
2026
Q1
– Sell
-28,559
Closed -$515K – 4605
2025
Q4
$515K Buy
+28,559
New +$513K ﹤0.01% 3919
2025
Q3
– Sell
-18,854
Closed -$302K – 4598
2025
Q2
$302K Sell
18,854
-227,488
-92% -$4.06M ﹤0.01% 3869
2025
Q1
$4.79M Sell
246,342
-864,159
-78% -$18.2M ﹤0.01% 1924
2024
Q4
$24.5M Buy
1,110,501
+155,086
+16% +$2.98M 0.02% 917
2024
Q3
$16.1M Buy
955,415
+565,303
+145% +$8.39M 0.01% 1123
2024
Q2
$4.66M Sell
390,112
-335,034
-46% -$3.74M ﹤0.01% 1909
2024
Q1
$8.03M Buy
725,146
+254,038
+54% +$2.59M 0.01% 1532
2023
Q4
$4.08M Buy
471,108
+315,488
+203% +$2.45M ﹤0.01% 2071
2023
Q3
$1.19M Buy
155,620
+95,028
+157% +$713K ﹤0.01% 2957
2023
Q2
$436K Buy
+60,592
New +$353K ﹤0.01% 3474
2022
Q2
– Sell
-13,046
Closed -$83K – 5384
2022
Q1
$83K Sell
13,046
-2,698
-17% -$17.9K ﹤0.01% 5037
2021
Q4
$126K Buy
+15,744
New +$148K ﹤0.01% 5014

Other funds holding CLBT

David Shaw's CLBT Position: Q3 2026 in Review

David Shaw opened a new position in Cellebrite (CLBT) in Q3 2026: 290,230 shares worth $3.27M. The stake represents ﹤0.01% of the portfolio and ranks #2817 among its holdings. This is a return to the name: David Shaw previously reported a position in CLBT as recently as Q4 2025.

David Shaw first reported a position in CLBT in Q4 2021 and has held it in 13 quarters since. The position peaked at $24.5M in Q4 2024. 200 funds tracked by Wall St. Rank hold CLBT as of Q3 2026.

  • David Shaw held 290,230 shares of Cellebrite worth $3.27M as of Q3 2026.
  • Cellebrite was a new David Shaw position in Q3 2026.
  • Cellebrite made up ﹤0.01% of David Shaw's portfolio in Q3 2026, its #2817 holding.
  • David Shaw first reported a position in Cellebrite in Q4 2021 and has held it in 13 quarters since.
  • David Shaw's Cellebrite position peaked at $24.5M in Q4 2024.
  • 200 funds tracked by Wall St. Rank held Cellebrite as of Q3 2026.

Based on D.E. Shaw & Co's 13F filing for Q3 2026, filed 16 Nov 2026.